Tags

Type your tag names separated by a space and hit enter

CO(2) laser therapy of vulval lymphangiectasia and lymphangioma circumscriptum.
Dermatol Surg 2002; 28(7):575-7DS

Abstract

BACKGROUND

Lymphangiectasia is a disorder of superficial lymphatics resulting from obstruction of previously normal deep lymphatics, while lymphangioma circumscriptum describes a deep dermal and subcutaneous lymphatic malformation with secondary superficial ectatic changes. Previous case reports have suggested the effectiveness of CO2 laser treatment.

OBJECTIVE

To assess CO2 laser therapy for vulval involvement by these lymphatic disorders.

METHODS

A retrospective case review at St. John's Institute of Dermatology from 1996 to 1999 identified three women with vulval lymphangiectasia and two with vulval lymphangioma circumscriptum treated with the CO2 laser.

RESULTS

Patient tolerance of the procedure was good. Healing was complete within 1 month and occurred without change in skin texture. All patients reported considerable improvement in symptoms (mean follow-up 22 months, median 24 months, range 10-33 months). Focal recurrence and an area of localized persistence were noted in the two patients with lymphangioma circumscriptum.

CONCLUSION

CO2 laser therapy of vulval lymphangiectasia and lymphangioma circumscription is effective and well-tolerated; the latter may possibly be more resistant to treatment than the former.

Authors+Show Affiliations

St. Thomas' Hospital, London, United Kingdom.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12135508

Citation

Huilgol, Shyamala C., et al. "CO(2) Laser Therapy of Vulval Lymphangiectasia and Lymphangioma Circumscriptum." Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], vol. 28, no. 7, 2002, pp. 575-7.
Huilgol SC, Neill S, Barlow RJ. CO(2) laser therapy of vulval lymphangiectasia and lymphangioma circumscriptum. Dermatol Surg. 2002;28(7):575-7.
Huilgol, S. C., Neill, S., & Barlow, R. J. (2002). CO(2) laser therapy of vulval lymphangiectasia and lymphangioma circumscriptum. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], 28(7), pp. 575-7.
Huilgol SC, Neill S, Barlow RJ. CO(2) Laser Therapy of Vulval Lymphangiectasia and Lymphangioma Circumscriptum. Dermatol Surg. 2002;28(7):575-7. PubMed PMID: 12135508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CO(2) laser therapy of vulval lymphangiectasia and lymphangioma circumscriptum. AU - Huilgol,Shyamala C, AU - Neill,Sallie, AU - Barlow,Richard J, PY - 2002/7/24/pubmed PY - 2002/8/14/medline PY - 2002/7/24/entrez SP - 575 EP - 7 JF - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JO - Dermatol Surg VL - 28 IS - 7 N2 - BACKGROUND: Lymphangiectasia is a disorder of superficial lymphatics resulting from obstruction of previously normal deep lymphatics, while lymphangioma circumscriptum describes a deep dermal and subcutaneous lymphatic malformation with secondary superficial ectatic changes. Previous case reports have suggested the effectiveness of CO2 laser treatment. OBJECTIVE: To assess CO2 laser therapy for vulval involvement by these lymphatic disorders. METHODS: A retrospective case review at St. John's Institute of Dermatology from 1996 to 1999 identified three women with vulval lymphangiectasia and two with vulval lymphangioma circumscriptum treated with the CO2 laser. RESULTS: Patient tolerance of the procedure was good. Healing was complete within 1 month and occurred without change in skin texture. All patients reported considerable improvement in symptoms (mean follow-up 22 months, median 24 months, range 10-33 months). Focal recurrence and an area of localized persistence were noted in the two patients with lymphangioma circumscriptum. CONCLUSION: CO2 laser therapy of vulval lymphangiectasia and lymphangioma circumscription is effective and well-tolerated; the latter may possibly be more resistant to treatment than the former. SN - 1076-0512 UR - https://www.unboundmedicine.com/medline/citation/12135508/CO_2__laser_therapy_of_vulval_lymphangiectasia_and_lymphangioma_circumscriptum_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1076-0512&date=2002&volume=28&issue=7&spage=575 DB - PRIME DP - Unbound Medicine ER -